The global vaginal and vulval inflammatory diseases treatment market is expected to be valued at USD 2.96 Billion in the fiscal year 2023, up from USD 2.8 Billion in 2022. With a steady CAGR of 5.8% anticipated from 2023 to 2033, the market is projected to reach approximately USD 5.21 Billion by the end of the forecast period.
This growth is indicative of the increasing awareness and focus on women’s health issues, alongside the continuous development of effective treatments for vaginal and vulval inflammatory diseases. As healthcare providers and pharmaceutical companies enhance their offerings, patients will benefit from improved therapeutic options, contributing to the overall expansion of this vital market segment. The sustained investment in research and development further underscores the commitment to addressing the needs of women affected by these conditions.
Both vulvitis (vulval inflammation) and vaginitis (vaginal inflammation) refer to inflammation of the female reproductive organs. Vulvitis is an infection of the genitals, or vulva – the outermost portion of the female reproductive anatomy. Vaginitis is an inside-the-body inflammation that damages the vagina. Vulvovaginitis is an inflammation that affects both the vulva and the vagina. These inflammatory disorders are typically brought on by yeast, candida species, or candida Albicans. Atypical vaginal discharge, dyspareunia, external dysuria, vaginal discomfort, and pruritis are a few signs of vaginal and vulval inflammation.
Approximately 75% of women are expected to have vaginal and vulval inflammation at least once, and 42% to 45% of women may experience the illness twice or more, according to statistics from the Centers for Disease Control and Prevention. Depending on the clinical presentation, the microbiology, the host characteristics, and the response to treatment, this illness is categorized as difficult or simple.
In most cases, the problem necessitates consulting a gynecologist or simply a nurse practitioner. Antifungal drugs can be used to diagnose and treat vaginal and vulval irritation. Although vaginal and vulval inflammation may usually be managed in a few days, more serious instances may require extended periods of therapy. Such factors have been boosting the treatment market for vaginal and vulval inflammations during the forecast period.
Competitive Landscape
Some of the prominent players in the global market for vaginal and vulval inflammatory diseases treatment are:
- Almirall
- VenusConcept
- ThermiGen LLC
- Lutronic
- BTL Group of Companies
- Viveve
- Fotona
- Evofem Biosciences, Inc.
- Spero Therapeutics
- Hologic
- Kyung Hee University Hospital
Some of the prominent developments of the key players in the market are:
- Evofem Biosciences, Inc. presented additional results from the Phase 3 EMPOWER clinical study of Phexxi (lactic acid, citric acid, and potassium bitartrate) in May 2022, revealing that women who participated in the EMPOWER trial had fewer urinary tract infections (UTIs) than the general population. In order to fill immediate needs in women’s reproductive and sexual health, Evofem Biosciences, Inc. is creating and marketing novel solutions, such as hormone-free, woman-controlled contraception and gonorrhea and chlamydia protection. Phexxi® (lactic acid, citric acid, and potassium bitartrate), the company’s first FDA-approved medication, is a hormone-free, prescription-only vaginal gel contraception.
- The US Food and Drug Administration (USFDA) approved Priority Review for Spero Therapeutics’ tebipenem HBr (tebipenem pivoxil hydrobromide) New Drug Registration in January 2022 for the therapy of individuals with complex urinary tract infections (cUTI) as well as inflammations, especially pyelonephritis, caused by sensitive bacteria.
Key Companies Profiled
- Almirall
- VenusConcept
- ThermiGen LLC
- Lutronic
- BTL Group of Companies
- Viveve
- Fotona
- Hologic
- Kyung Hee University Hospital
Key Segments Covered In The Vaginal And Vulval Inflammatory Diseases Treatment Market Report
Vaginal And Vulval Inflammatory Diseases Treatment Market By Indication:
- Vaginal Dryness
- Vaginal Burning
- Vaginal Discharge
- Genital Itching
- Recurrent Urinary Tract Infections
- Urinary Incontinence
- Others
Vaginal And Vulval Inflammatory Diseases Treatment Market By Treatment:
- Anti-Itch Medications
- Corticosteroid Ointments
- Anti-Itch Emollients
Vaginal And Vulval Inflammatory Diseases Treatment Market By End User:
- Hospital Pharmacies
- Specialty Clinics
- Others
Vaginal and Vulval Inflammatory Diseases Treatment Market By Region:
- North America
- Latin America
- Asia Pacific
- Europe
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube